Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-β

doi:10.1007/s10875-021-01068-6

Editorial

. 2021 Oct;41(7):1425-1442.

doi: 10.1007/s10875-021-01068-6. Epub 2021 Jun 8.

Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-β

Donald C Vinh¹, Laurent Abel^{2

3

4}, Paul Bastard^{2

3

4}, Matthew P Cheng¹, Antonio Condino-Neto⁵, Peter K Gregersen⁶, Filomeen Haerynck⁷, Maria-Pia Cicalese⁸, David Hagin⁹, Pere Soler-Palacín¹⁰, Anna M Planas¹¹, Aurora Pujol^{12

13}, Luigi D Notarangelo¹⁴, Qian Zhang², Helen C Su¹⁴, Jean-Laurent Casanova^{2

3

4

15}, Isabelle Meyts^{16

17}; COVID Human Genetic Effort

Collaborators, Affiliations

Collaborators

COVID Human Genetic Effort:
Alessandro Aiuti, Lisa M Arkin, Alexandre Bolze, Samya Charkravorty, John Christodoulou, Roger Colobran, Beth A Drolet, Jacques Fellay, Pr Antoine Froidure, Jean William Pape, Rabih Halwani, Trine H Mogensen, Giuseppe Novelli, Igor B Resnick, Anna Sediva, Ivan Tancevski, Stuart Turvey

Affiliations

¹ McGill University Health Centre, Montreal, Canada.
² St Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY, 10065, USA.
³ Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR 1163, Necker Hospital for Sick Children, 75015, Paris, France.
⁴ University of Paris, Imagine Institute, 75015, Paris, France.
⁵ University of São Paulo, São Paulo, Brazil.
⁶ Feinstein Institute for Medical Research, Northwell Health USA, Manhasset, NY, USA.
⁷ Department of Paediatric Immunology and Pulmonology, Centre for Primary Immunodeficiency Ghent (CPIG), PID Research Lab, Jeffrey Modell Diagnosis and Research Centre, Ghent University Hospital, Ghent University, Ghent, Belgium.
⁸ Pediatric Immunohematology and Bone Marrow Transplantation Unit, San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.
⁹ Allergy and Clinical Immunology Unit, Department of Medicine, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv, Israel.
¹⁰ Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona (UAB), Barcelona, Catalonia, Spain.
¹¹ IIBB-CSIC, IDIBAPS, Barcelona, Catalonia, Spain.
¹² Neurometabolic Diseases Laboratory, IDIBELL-Hospital Duran I Reynals; Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Catalonia, Spain.
¹³ CIBERER U759, ISCiii, Madrid, Spain.
¹⁴ Laboratory of Clinical Immunology and Microbiology, National Institutes of Health, Bethesda, MD, USA.
¹⁵ Howard Hughes Medical Institute, New York, NY, USA.
¹⁶ Department of Pediatrics, University Hospitals Leuven, Leuven, Belgium. isabelle.meyts@uzleuven.be.
¹⁷ Laboratory for Inborn Errors of Immunity, KU Leuven, Leuven, Belgium. isabelle.meyts@uzleuven.be.

PMID: 34101091
PMCID: PMC8186356
DOI: 10.1007/s10875-021-01068-6

Editorial

Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-β

Donald C Vinh et al. J Clin Immunol. 2021 Oct.

. 2021 Oct;41(7):1425-1442.

doi: 10.1007/s10875-021-01068-6. Epub 2021 Jun 8.

Authors

Collaborators

COVID Human Genetic Effort:
Alessandro Aiuti, Lisa M Arkin, Alexandre Bolze, Samya Charkravorty, John Christodoulou, Roger Colobran, Beth A Drolet, Jacques Fellay, Pr Antoine Froidure, Jean William Pape, Rabih Halwani, Trine H Mogensen, Giuseppe Novelli, Igor B Resnick, Anna Sediva, Ivan Tancevski, Stuart Turvey

Affiliations

¹ McGill University Health Centre, Montreal, Canada.
² St Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY, 10065, USA.
³ Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR 1163, Necker Hospital for Sick Children, 75015, Paris, France.
⁴ University of Paris, Imagine Institute, 75015, Paris, France.
⁵ University of São Paulo, São Paulo, Brazil.
⁶ Feinstein Institute for Medical Research, Northwell Health USA, Manhasset, NY, USA.
⁷ Department of Paediatric Immunology and Pulmonology, Centre for Primary Immunodeficiency Ghent (CPIG), PID Research Lab, Jeffrey Modell Diagnosis and Research Centre, Ghent University Hospital, Ghent University, Ghent, Belgium.
⁸ Pediatric Immunohematology and Bone Marrow Transplantation Unit, San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.
⁹ Allergy and Clinical Immunology Unit, Department of Medicine, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv, Israel.
¹⁰ Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona (UAB), Barcelona, Catalonia, Spain.
¹¹ IIBB-CSIC, IDIBAPS, Barcelona, Catalonia, Spain.
¹² Neurometabolic Diseases Laboratory, IDIBELL-Hospital Duran I Reynals; Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Catalonia, Spain.
¹³ CIBERER U759, ISCiii, Madrid, Spain.
¹⁴ Laboratory of Clinical Immunology and Microbiology, National Institutes of Health, Bethesda, MD, USA.
¹⁵ Howard Hughes Medical Institute, New York, NY, USA.
¹⁶ Department of Pediatrics, University Hospitals Leuven, Leuven, Belgium. isabelle.meyts@uzleuven.be.
¹⁷ Laboratory for Inborn Errors of Immunity, KU Leuven, Leuven, Belgium. isabelle.meyts@uzleuven.be.

PMID: 34101091
PMCID: PMC8186356
DOI: 10.1007/s10875-021-01068-6

No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Cited by

A Thermosensitive and Degradable Chitin-Based Hydrogel as a Brucellosis Vaccine Adjuvant.
Ju R, Lu Y, Jiang Z, Chi J, Wang S, Liu W, Yin Y, Han B. Ju R, et al. Polymers (Basel). 2024 Oct 4;16(19):2815. doi: 10.3390/polym16192815. Polymers (Basel). 2024. PMID: 39408526 Free PMC article.
COVID-19 and Inborn Errors of Immunity.
Delmonte OM, Castagnoli R, Notarangelo LD. Delmonte OM, et al. Physiology (Bethesda). 2022 Nov 1;37(6):0. doi: 10.1152/physiol.00016.2022. Epub 2022 Aug 9. Physiology (Bethesda). 2022. PMID: 35944006 Free PMC article. Review.
Interferon at the crossroads of SARS-CoV-2 infection and COVID-19 disease.
Samuel CE. Samuel CE. J Biol Chem. 2023 Aug;299(8):104960. doi: 10.1016/j.jbc.2023.104960. Epub 2023 Jun 24. J Biol Chem. 2023. PMID: 37364688 Free PMC article. Review.
Polymorphism in interferon alpha/beta receptor contributes to glucocorticoid response and outcome of ARDS and COVID-19.
Jalkanen J, Khan S, Elima K, Huttunen T, Wang N, Hollmén M, Elo LL, Jalkanen S. Jalkanen J, et al. Crit Care. 2023 Mar 16;27(1):112. doi: 10.1186/s13054-023-04388-8. Crit Care. 2023. PMID: 36927455 Free PMC article. Clinical Trial.
Lipin-2 regulates the antiviral and anti-inflammatory responses to interferon.
de Pablo N, Meana C, Martínez-García J, Martínez-Vicente P, Albert M, Guerra S, Angulo A, Balsinde J, Balboa MA. de Pablo N, et al. EMBO Rep. 2023 Dec 6;24(12):e57238. doi: 10.15252/embr.202357238. Epub 2023 Nov 6. EMBO Rep. 2023. PMID: 37929625 Free PMC article.

See all "Cited by" articles

References

1. NIH. Clinical spectrum of SARS-CoV-2 infection December 17, 2020 [Available from: https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/.
1. Johns Hopkins University & Medicine CRC. https://coronavirus.jhu.edu/map.html 2021 [
1. Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370(6515). - PMC - PubMed
1. Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515). - PMC - PubMed
1. Zhang Q, Bastard P, Bolze A, Jouanguy E, Zhang SY, Effort CHG, et al. Life-threatening COVID-19: defective interferons unleash excessive inflammation. Med (N Y). 2020;1(1):14–20. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

[1] NIH. Clinical spectrum of SARS-CoV-2 infection December 17, 2020 [Available from: https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/.

[2] NIH. Clinical spectrum of SARS-CoV-2 infection December 17, 2020 [Available from: https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/.

[3] Johns Hopkins University & Medicine CRC. https://coronavirus.jhu.edu/map.html 2021 [

[4] Johns Hopkins University & Medicine CRC. https://coronavirus.jhu.edu/map.html 2021 [

[5] Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370(6515). - PMC - PubMed

[6] Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370(6515). - PMC - PubMed

[7] Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515). - PMC - PubMed

[8] Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515). - PMC - PubMed

[9] Zhang Q, Bastard P, Bolze A, Jouanguy E, Zhang SY, Effort CHG, et al. Life-threatening COVID-19: defective interferons unleash excessive inflammation. Med (N Y). 2020;1(1):14–20. - PMC - PubMed

[10] Zhang Q, Bastard P, Bolze A, Jouanguy E, Zhang SY, Effort CHG, et al. Life-threatening COVID-19: defective interferons unleash excessive inflammation. Med (N Y). 2020;1(1):14–20. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-β

Collaborators

Affiliations

Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-β

Authors

Collaborators

Affiliations

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous